SAN DIEGO, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its third quarter 2016 financial results after the market closes on Thursday, November 3, 2016 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 1402125. Participants may access the live webcast via a link on the Vital Therapies website in the ‘Investor Relations’ section under ‘Events’ at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on November 3, 2016 to November 10, 2016. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 1402125.
Upcoming Investor Conferences
Additionally, the Company will be presenting at the following investor conferences:
- The 25th Annual Credit Suisse Healthcare Conference on Tuesday, November 8 at 9:00 AM Pacific in Scottsdale, AZ.
- The Stifel 2016 Healthcare Conference on Wednesday, November 16 at 11:15 AM Pacific in New York City.
A live webcast of each presentation will be available via the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of each presentation will be available for replay via the site as well.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact: Vital Therapies, Inc. Al Kildani Vice President, Investor Relations and Business Development 858-673-6840 email@example.com
Source:Vital Therapies, Inc.